Cellenkos Inc., an early stage clinical biotechnology company recently announced initiation of Phase 1 clinical trial of CK0801 for treatment of bone marrow failure syndromes, including primary myelofibrosis, hypoplastic myelodysplasia & aplastic anemia, cites source.

For the record, bone marrow failure syndrome denotes a group of life-threatening diseases with malfunctioned production of white blood cells (that lead to severe infection), red blood cells (that leads to anemia) & platelets (that leads to bleeding). Uncontrolled inflammation, immune dysfunction & defective T-regulatory cells propagate bone marrow failure syndromes.

Bone marrow failure syndrome is indicated by disease-driving cytotoxic T-cells’ uncontrolled attacks leading to an inflammatory microenvironment & inhibited normal blood cell production in the bone marrow. CK0801 supplies healthy regulatory T-cells to suppress cytotoxic T-cells & bone marrow inflammation and aids normalization of blood cell production.

As per credible sources, CK0801 is developed from Cellenkos' patented manufacturing platform and is allogeneic, cord blood-derived T-regulatory cell product. It inhibits key drivers of inflammation to overcome immune dysfunction. It contains healthy regulatory T-cells that are derived from healthy donor’s cord blood units. CK0801 is manufactured at Cellenkos’ GMP manufacturing facility, Texas. In June 2018, first CK0801 was approved by USFDA.

Elizabeth J. Read, MD & Chief Technology Officer, Cellenkos was reportedly quoted saying that clinical trial of CK0801 for bone marrow failure syndromes is a significant event for Cellenkos. The company’s programs include advancement of cord blood-derived T-regulatory cells products which are used for treatment of hematologic diseases, neuro-inflammatory disorders, graft vs. host disease & autoimmune diseases. The company aims at validating the cellular product as safe & capable of providing clinical benefit to range of serious illnesses.

As per sources close to the matter, the clinical trial of CK0801 will be led by Tapan Kadi (MD, Assistant Professor of Leukemia at University of Texas MD Anderson Cancer Center, Texas).

Source credits: https://finance.yahoo.com/news/cellenkos-inc-initiates-phase-1-131700344.html